Artist’s rendition of virus particles

Comprehensive, end-to-end solutions to support your vaccine development

Thermo Fisher Scientific is an industry-leading, trusted partner offering innovative products and technologies for vaccine development. With the coronavirus (2019-nCov) outbreak, we are committed to helping researchers interested in rapidly developing mRNA-based vaccines with secure supply chains of critical raw materials for mRNA therapeutics.

Workflow diagram showing an overview of the steps from gene synthesis to delivery of therapeutic reagent

Building your gene, with 100% accuracy

Our GeneArt Gene Synthesis materials are produced using cutting edge semi-conductor technology. Using femtomole quantities, our processes help reduce errors associated with high-throughput gene synthesis.

GeneArt Gene Synthesis Services offer:

  • Proprietary optimization of expression and mRNA stability using the multi-factorial GeneArt GeneOptimizer algorithm
  • Synthesis of very large and complex gene sequences
  • Nearly unlimited flexibility in gene and vector design
  • Ready-to-use constructs for expression and transfection
  • Project setup assistance and individual project support
  • Rapid synthesis and assembly as few as 5 business days with SuperSPEED production

Ready to start designing your DNA? Place your order with GeneArt Gene Synthesis Services today!

Explore all of GeneArt gene synthesis products at thermofisher.com/genesynthesis

Critical raw material for mRNA synthesis

TheraPure-grade reagents for mRNA therapeutics contain highest level of purity and are manufactured using high-definition analytics and tightly controlled purity standards. Our TheraPure-grade portfolio (Table 1) offers a unique integrated solution for mRNA synthesis, optimized to meet fit-for-purpose standards:

  • Animal origin-free (AOF) and ampicillin-free (AF) components throughout the manufacturing process (e.g., from fermentation to enzyme formulation)
  • Greater than 99% triphosphate for NTPs and modified nucleotides as determined by HPLC
  • Tested for critical impurities, e.g., endotoxin, bioburden, residual metals, host cell DNA, RNase and DNase activities

 

Table 1. In vitro transcription TheraPure-grade product portfolio.

In vitro transcription Posttranscriptional modification Template degradation
T7 RNA polymerase, TheraPure-grade Capping enzymes, TheraPure-grade DNase I, TheraPure-grade
RNase inhibitor, TheraPure-grade  2’–O-methyltransferase, TheraPure-grade
Inorganic Pyrophosphatase, TheraPure-grade Poly(A) polymerase, TheraPure-grade
ATP, GTP, CTP and UTP, TheraPure-grade
Modified nucleotides, TheraPure-grade
ARCA (anti-reverse cap analog)

Need customization or ready to order? Contact us today

Learn more about our mRNA-based therapeutics workflow solutions

Related resources